Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023;55(3):241-242.
doi: 10.5114/ait.2023.130640.

Reply to the Commentary on "An appraisal of neostigmine versus sugammadex for neuromuscular blockade reversal in patients with a prior heart transplant"

Stephania Paredes  1 , Vivian Hernandez Torres  2 , Harold Chaves-Cardona  2 , Steven Porter  2 , Johnathan Ross Renew  2
Affiliations
Comment

Reply to the Commentary on "An appraisal of neostigmine versus sugammadex for neuromuscular blockade reversal in patients with a prior heart transplant"

Stephania Paredes et al. Anaesthesiol Intensive Ther. 2023.
No abstract available

PubMed Disclaimer

Conflict of interest statement

none.

Comment on

References

    1. Chowdhury SR, Baidya DK. Commentary on “An appraisal of neostigmine versus sugammadex for neuromuscular blockade reversal in patients with a prior heart transplant”. Anesthesiol Intensive Ther 2023; 55: 240. doi: 10.5114/ait.2023.130638. - DOI - PMC - PubMed
    1. Food and Drug Administration . BRIDION® (sugam-madex) Injection, for intravenous use. [Internet]. 2015. [cited 2020 Feb 14]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022225lbl.pdf.
    1. Adams DR, Tollinche LE, Yeoh CB, et al. . Short-term safety and effectiveness of sugammadex for surgical patients with end-stage renal disease: a two-centre retrospective study. Anaesthesia 2020; 75: 348-352. doi: 10.1111/anae.14914. - DOI - PMC - PubMed
    1. Paredes S, Porter SB, Porter IE, Renew JR. Sugammadex use in patients with end-stage renal disease: a historical cohort study. Can J Anesth 2020; 67: 1789-1797. doi: 10.1007/s12630-020-01812-3. - DOI - PubMed
    1. Kim YS, Lim BG, Won YJ, Oh SK, Oh JS, Cho SA. Efficacy and safety of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in patients with end-stage renal disease: a systematic review and meta-analysis. Medicina (Kaunas) 2021; 57: 1259. doi: 10.3390/medicina57111259. - DOI - PMC - PubMed